Literature DB >> 25617182

Opioid misuse among adolescents: new evidence from a misclassification analysis.

Sean M Murphy1, Daniel L Friesner, Robert Rosenman.   

Abstract

BACKGROUND: Non-medical prescription-opioid (NMPO) use has been declared a national epidemic in the US. Opioid misuse is associated with substantial physiological, psychological, and concomitant economic implications. NMPO use among adolescents warrants special attention given its prevalence and the high risk of addiction.
OBJECTIVES: Our objectives were to: (a) identify factors associated with adolescent NMPO use after controlling for misclassification, while simultaneously identifying characteristics that affected the likelihood of misreporting use; and (b) identify factors associated with an individual misusing their own versus a diverted prescription, and the likelihood that the prescription source was misreported.
METHODS: Data come from the Washington State Healthy Youth Survey. A maximum likelihood estimation technique for systematically misclassified binary-dependent variables was utilized. Covariates were chosen to represent influential factors identified in the theoretical adolescent development literature.
RESULTS: An estimated 35 % of respondents who stated that they had never misused prescription opioids most likely had. An estimated 17 % of those who admitted to NMPO use claimed to have misused a diverted prescription, but most likely misused their own. Various demographic, school, neighborhood, family, substance-use, personality/attitude, and social factors were identified as potential predictors of adolescent NMPO use, opioid-prescription source, and misclassification of responses to each outcome.
CONCLUSIONS: The finding that a self-reported survey failed to identify over one-third of individuals at risk for NMPO use is concerning, as is the finding that approximately 17 % of those who admitted to NMPO use may have misstated their prescription-opioid source. The findings presented here are critical to focus prevention efforts, especially for identifying at-risk youths who may misrepresent their use.

Entities:  

Mesh:

Year:  2015        PMID: 25617182     DOI: 10.1007/s40258-015-0151-z

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  5 in total

1.  Dental opioid prescribing and multiple opioid prescriptions among dental patients: Administrative data from the South Carolina prescription drug monitoring program.

Authors:  Jenna L McCauley; J Madison Hyer; V Ramesh Ramakrishnan; Renata Leite; Cathy L Melvin; Roger B Fillingim; Christie Frick; Kathleen T Brady
Journal:  J Am Dent Assoc       Date:  2016-04-05       Impact factor: 3.634

2.  The "Real" Number of Washington State Adolescents Using Marijuana, and Why: A Misclassification Analysis.

Authors:  Sean M Murphy; Robert Rosenman
Journal:  Subst Use Misuse       Date:  2018-10-26       Impact factor: 2.164

3.  Opioid use disorder and overdose among youth following an initial opioid prescription.

Authors:  Scott E Hadland; Sarah M Bagley; Mam Jarra Gai; Joel J Earlywine; Samantha F Schoenberger; Jake R Morgan; Joshua A Barocas
Journal:  Addiction       Date:  2021-04-06       Impact factor: 7.256

4.  Evaluating the Effectiveness of a Web-Based Program (POP4Teens) to Prevent Prescription Opioid Misuse Among Adolescents: Randomized Controlled Trial.

Authors:  Lisa A Marsch; Sarah K Moore; Michael Grabinski; Sarah Y Bessen; Jacob Borodovsky; Emily Scherer
Journal:  JMIR Public Health Surveill       Date:  2021-02-25

Review 5.  Guidelines for Opioid Prescribing in Children and Adolescents After Surgery: An Expert Panel Opinion.

Authors:  Lorraine I Kelley-Quon; Matthew G Kirkpatrick; Robert L Ricca; Robert Baird; Calista M Harbaugh; Ashley Brady; Paula Garrett; Hale Wills; Jonathan Argo; Karen A Diefenbach; Marion C W Henry; Juan E Sola; Elaa M Mahdi; Adam B Goldin; Shawn D St Peter; Cynthia D Downard; Kenneth S Azarow; Tracy Shields; Eugene Kim
Journal:  JAMA Surg       Date:  2021-01-01       Impact factor: 14.766

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.